SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Anthera Pharmaceuticals, Inc. (ANTH)

ANTH RSS Feed
Add ANTH Price Alert      Hide Sticky   Hide Intro
Moderator: Klinsmann
Search This Board: 
Last Post: 4/21/2017 1:37:34 PM - Followers: 66 - Board type: Free - Posts Today: 0


 


 Anthera Pharmaceuticals Inc.     


                                              Nasdaq: ANTH


 

Anthera Pharmaceuticals is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company has two product candidates in development.

 

Sollpura is Anthera’s novel biotechnology-derived pancreatic enzyme replacement therapy for the potential treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

Blisibimod is Anthera’s BAFF inhibitor for the potential treatment of systemic lupus erythematosus and IgA nephropathy.


Pipeline



                            Contact Info                                                                           
                                                                           

Anthera Pharmaceuticals, Inc. 

25801 Industrial Blvd, Suite B • Hayward, CA 94545



Press Contact: pr@anthera.com


Business Development: bd@anthera.com


 Vendors: ap@anthera.com


 Website: www.anthera.com

 

------>>Latest Developments<<-----

December 06, 2016

J. Craig Thompson promoted to Chief Executive Officer and appointed to the Board of Directors Paul F. Truex appointed as Executive Chairman of the Board Dr. Christopher Henney stepped down as Chairman ...

1
 
         
___________________________________________________________________________________________________________________________________________
Outstanding Share Data
October 31 ,2016,the Company had 41,955,126 common shares issued and outstanding
July 31,2016 the Company had 41,427,352 common shares issued and outstanding
April 27,2016 the Company had 40,987,145 common shares issued and outstanding
February 29,2016 the Company had 40,004,037 common shares issued and outstanding
November 1,2015 the Company had 39,875,405 common shares issued and outstanding
August 1,2015 the Company had 39,703,998 common shares issued and outstanding
May 1,2015 the Company had 35,816,364 common shares issued and outstanding
February 28,2015 the Company had 29,091,773 common shares issued and outstanding
November 10,2014 the Company had 22,939,553 common shares issued and outstanding
____________________________________________________________________________________________________________________________________________

MAJOR HOLDERS

 

68% of the outstanding owned by these longs

Outstanding 42mil minus Major ownership of 28.5mil = 13.5mil free trading float


28.5mil Major Holders in this,15mil Institutions,7.5mil Direct Holders,6mil Mutual Funds= 68% of 42mil os 


http://www.barrons.com/quote/stock/us/xnas/anth?mod=DNH_S

________________________________________________________________


http://finance.yahoo.com/q?s=ANTH

   Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation,

including cardiovascular and autoimmune diseases. We currently have a Phase 2 clinical program, blisibimod.It was just recently approved by FDA to move into

PHASE 3

 

   Blisibimod targets elevated levels of B-cell activating factor (BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others.


  It has taken the lupus research community over 50 years to produce a new therapy. Although it is now a year old, Benlysta (belimumab),

now marketed by GlaxoSmithKline and Human Genome Sciences, is the first human monoclonal antibody for the treatment

of lupus.




  Benlysta had a slow take-off grossing $59.2 million in sales in the last three quarters of 2011, but it was approved in numerous

countries by year's end.
Estimated sales for Benlysta in 2012 are said to be about $230 million, with first annual profits likely by 2015.


  The surprisingly slow uptake of Benlysta allows for blisibimod to develop into a promising drug as

it currently has more desirable features than that of Benlysta.


Blisibimod has a dosing regimen of one injection weekly, compared to that of Benlysta which requires a

series of dosing before the maintenance dose begins. Also, Benlysta has limitations on usage pertaining to

specific patient populations and has not been studied in combination with other biologics.

These attributes of blisibimod including a different mechanism of action, will set it apart from

Benlysta, Global Data concludes.

 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ANTH
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ANTH News: Amended Statement of Ownership (sc 13g/a) 04/10/2017 12:02:50 PM
ANTH News: Anthera Announces Completion of Dosing in the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy 04/10/2017 08:00:00 AM
ANTH News: Current Report Filing (8-k) 03/31/2017 06:11:15 AM
ANTH News: Anthera Announces Positive Results from the Extension Period of the SOLUTION Study of Sollpura 03/29/2017 04:05:00 PM
ANTH News: Statement of Ownership (sc 13g) 03/20/2017 04:04:31 PM
PostSubject
#2068   Quiet in here nothing happening? PirateGary 04/21/17 01:37:34 PM
#2067   Nice additional news for ANTH today. Bottom in Klinsmann 04/10/17 11:28:47 AM
#2066   awesome ... I pulled my big order but duder54 04/07/17 11:42:38 AM
#2065   I added this morning. ksuave 04/07/17 11:36:49 AM
#2064   looking forward to the reversal. Lets see what duder54 04/07/17 11:30:39 AM
#2063   Positive results means a lot to a biotech Klinsmann 04/07/17 11:19:38 AM
#2062   I think of it as a hissy fit duder54 04/07/17 11:06:40 AM
#2061   To you as well! 0,50 test gonna happen imo Klinsmann 04/07/17 10:47:50 AM
#2060   This area I think is safe. but the duder54 04/07/17 10:44:38 AM
#2059   0,37/0,38 looks like a smart and safe entry Klinsmann 04/07/17 10:36:27 AM
#2058   it seems like a bear rad. not worried. duder54 04/07/17 10:33:39 AM
#2057   On the sidelines again - the bears took Klinsmann 04/07/17 10:06:48 AM
#2056   Double bottom on chart doji or sold white duder54 04/07/17 07:56:40 AM
#2055   Any upward tendencies have been beaten down, a Klinsmann 04/07/17 12:18:10 AM
#2054   So where is the bottom here, seems to Mark 04/06/17 11:05:30 PM
#2053   A bid strange that it went down on Klinsmann 04/02/17 12:32:08 PM
#2052   Whoopi!! I think the major selling has ended Masala 04/02/17 12:02:19 PM
#2051   Now finally headed in the right direction on Klinsmann 03/31/17 03:36:56 PM
#2050   stockcharts.com/c-sc/sc?s=ANTH&p=D&b=5&g=0&i=0&r=1490964875789 Klinsmann 03/31/17 08:55:15 AM
#2049   No problem so far, they raised capital like Klinsmann 03/31/17 03:18:31 AM
#2048   I thought so. Looks like they must sold into bbhuey 03/30/17 06:02:58 PM
#2047   Wasn´t it positive news for ANTH?!? Klinsmann 03/30/17 11:47:27 AM
#2046   Pure selling on that gapper - right now Klinsmann 03/30/17 09:41:46 AM
#2045   200k @ask - went from 0,50 to 0,48 Klinsmann 03/30/17 08:23:11 AM
#2044   Same here - nice day ahead :) Klinsmann 03/30/17 02:50:14 AM
#2043   Looks good for tomorrow, locked and loaded Mark 03/29/17 06:24:25 PM
#2042   Great news here finally - already gapping up AH Klinsmann 03/29/17 05:02:40 PM
#2041   Another bigger ask position broken quickly this morning! Klinsmann 03/29/17 09:44:25 AM
#2040   Nice surge in volume eod Klinsmann 03/27/17 04:13:58 PM
#2039   May have been a good question 4 weeks ago... Klinsmann 03/27/17 02:50:24 PM
#2038   How low will this go? righlife 03/27/17 02:32:09 PM
#2037   Great day so far! Looks ready for 0,43 break... Klinsmann 03/27/17 11:57:30 AM
#2036   Took a starter, looks like bottom might be Klinsmann 03/23/17 02:13:54 PM
#2035   ANTH HIRES DR.J & DR.DRE TO THE TEAM. Tom Trady 03/23/17 12:17:14 PM
#2034   anth hires Dr.David Banner, a good guy but Tom Trady 03/23/17 01:21:08 AM
#2033   0,40 break could bring some more damage to Klinsmann 03/22/17 10:02:40 AM
#2032   This is So close to .45 gap full. moneyman419 03/17/17 03:23:36 PM
#2031   Snagged some ¬©PROPHETABLE 03/17/17 11:58:52 AM
#2030   usually not a good sign when Sabby is Atlanta1 03/15/17 01:06:14 PM
#2029   $ANTH - got out AH at $.425 yesterday Atlanta1 03/15/17 09:47:25 AM
#2028   On watch - too early to enter imo. Klinsmann 03/14/17 10:11:19 AM
#2027   $ANTH - in avg. .416 for a bounce Atlanta1 03/14/17 09:46:16 AM
#2026   .46 premarket, glad i sold $ANTH @.72 couple trop 03/14/17 08:20:35 AM
#2025   i think this will come back . NewTrader2017 03/13/17 04:51:12 PM
#2024   Whoops Awl416 03/13/17 04:49:03 PM
#2023   16:02 Anthera Pharma intends to offer and sell shares Atlanta1 03/13/17 04:04:18 PM
#2022   better take another look at the filing.... Atlanta1 03/05/17 03:01:45 AM
#2021   Management scooped up 100,000 common shares @ .64 Porsche 911 03/05/17 02:49:33 AM
#2020   Poor ClayTraders getting squeezed on this haha Dan121 03/02/17 02:25:43 PM
#2019   Ok Thx europtiger 03/01/17 01:30:47 PM
PostSubject